Evidence map›Paper›PMID 25220242›Full record

ArticleEuropean journal of pharmacology2014

Effects of the neuropeptide S receptor antagonist RTI-118 on abuse-related facilitation of intracranial self-stimulation produced by cocaine and methylenedioxypyrovalerone (MDPV) in rats.

Julie S Bonano, Scott P Runyon, Carla Hassler, Richard A Glennon, S Stevens Negus

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. A Role for Neuropeptide S in Alcohol and Cocaine Seeking.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142.The Journal of pharmacology and experimental therapeutics · 2018
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Agonist Medications for the Treatment of Cocaine Use Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Julie S BonanoDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 North 12th Street, PO Box 980613, Richmond, VA 23298, USA. Electronic address: bonanojs@vcu.edu.
Scott P RunyonOrganic and Medicinal Chemistry, Research Triangle Institute, 3040 East Cornwallis Road, PO Box 12194, Research Triangle Park, NC 27709, USA.
Carla HasslerOrganic and Medicinal Chemistry, Research Triangle Institute, 3040 East Cornwallis Road, PO Box 12194, Research Triangle Park, NC 27709, USA.
Richard A GlennonDepartment of Medicinal Chemistry, Virginia Commonwealth University, 1101 East Marshall Street, PO Box 980551, Richmond, VA 23298, USA.
S Stevens NegusDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 North 12th Street, PO Box 980613, Richmond, VA 23298, USA.
Virginia Commonwealth University · USRTI International · US

Funding

Medications Development for Stimulant AbuseR01DA026946 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S · 2009 to 2019
$3.7M
Synthetic cathinones: a new class of illicit drugs affecting DAT & SERTR01DA033930 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ELTIT, JOSE MIGUEL, GLENNON, RICHARD A · 2012 to 2016
$2.7M
Small Molecule Probes of the Neuropeptide S ReceptorR01MH087826 · NIMH · RESEARCH TRIANGLE INSTITUTE · PI RUNYON, SCOTT P · 2010 to 2014
$2.4M
Small Molecules for the Neuropeptide S Receptor SystemR21MH081247 · NIMH · RESEARCH TRIANGLE INSTITUTE · PI RUNYON, SCOTT P · 2007 to 2008
$502k
Structural determinants of abuse-related effects of synthetic cathinone analogsF30DA037649 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI SUYAMA, JULIE ANNA · 2014 to 2017
$112k
NIDA NIH HHS F30 DA037649NIDA NIH HHS F30DA037649NIDA NIH HHS R01 DA026946NIDA NIH HHS R01DA026946NIDA NIH HHS R01 DA033930NIDA NIH HHS R01DA033930NIMH NIH HHS R01 MH081247NIMH NIH HHS R01 MH087826NIMH NIH HHS R21 MH081247
6 · The paper itself

Abstract

Neuropeptide S (NPS) is a neurotransmitter that activates the NPS receptor to modulate biological functions including anxiety-like behaviors, feeding, and drug reinforcement. RTI-118 is a novel NPS receptor antagonist that decreased cocaine self-administration in rats at doses that had little or no effect on food-maintained responding. To build on these previous findings, this study examined effects of RTI-118 on cocaine-induced facilitation of intracranial self-stimulation (ICSS) in rats. To provide a context for data interpretation, effects of RTI-118 were compared to effects of the kappa opioid receptor agonist U69,593, because the kappa opioid receptor is another peptide neurotransmitter receptor reported to modulate abuse-related cocaine effects. RTI-118 effects were also examined on ICSS facilitation produced by methylenedioxypyrovalerone (MDPV), a novel designer drug of abuse with some cocaine-like effects. Male Sprague-Dawley rats (n=12) with electrodes targeting the medial forebrain bundle responded under a fixed-ratio 1 schedule for range of brain stimulation frequencies. Under control conditions, brain stimulation maintained a frequency-dependent increase in ICSS rates. Cocaine (1.0-10mg/kg) and MDPV (3.2mg/kg) facilitated ICSS. RTI-118 (3.2-32mg/kg) alone produced little effect on ICSS but dose dependently blocked cocaine-induced ICSS facilitation. U69,593 (0.25-0.5mg/kg) also attenuated cocaine effects, but blockade of cocaine effects was incomplete even at a U69,593 dose that alone depressed ICSS. RTI-118 (32mg/kg) failed to block MDPV-induced ICSS facilitation. These results support further consideration of NPS receptor antagonists as candidate treatments for cocaine abuse and provide evidence for differential effects of a candidate treatment on abuse-related effects of cocaine and MDPV.

Indexed as

AnimalsBenzodioxolesCHO CellsCocaineCocaine-Related DisordersCricetulusHEK293 CellsHumansMaleMedial Forebrain BundleNeuropeptidesPyrrolidinesRatsRats, Sprague-DawleyReceptors, NeuropeptideReceptors, Opioid, kappa3-(4'-chlorophenyl)-2-(5'-phenyl-1',3',4'-oxadiazol-2'-yl)tropaneBenzodioxolesCocaineNeuropeptidesPyrrolidinesReceptors, NeuropeptideReceptors, Opioid, kappaSynthetic CathinoneTropanesCocaineIntracranial self-stimulationMethylenedioxypyrovaleroneNeuropeptide SRTI-118

Identifiers

PMID25220242
PMCPMC4259821
OpenAlexW1973588841

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.